Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.
World J Hepatol. 2015 May 28;7(9):1192-208. doi: 10.4254/wjh.v7.i9.1192.
World J Hepatol. 2015.
PMID: 26019735
Free PMC article.
Review.
Non-alcoholic fatty liver disease (NAFLD) in the Western Cape: a descriptive analysis.
Kruger FC, Daniels C, Kidd M, Swart G, Brundyn K, Van Rensburg C, Kotze MJ.
Kruger FC, et al.
S Afr Med J. 2010 Mar 8;100(3):168-71. doi: 10.7196/samj.1422.
S Afr Med J. 2010.
PMID: 20459941
Item in Clipboard
APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, Kotze M.
Kruger FC, et al.
S Afr Med J. 2011 Jun 27;101(7):477-80.
S Afr Med J. 2011.
PMID: 21920102
Item in Clipboard
Caustic injury to the upper GI tract.
Kruger FC.
Kruger FC.
SADJ. 2004 Sep;59(8):335.
SADJ. 2004.
PMID: 15559920
Item in Clipboard
Severe pancoast tumour.
Kruger FC, Joubert JR, Bolliger CT.
Kruger FC, et al.
Respiration. 2000;67(3):315. doi: 10.1159/000029516.
Respiration. 2000.
PMID: 10867601
No abstract available.
Item in Clipboard
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group.
Kowdley KV, et al. Among authors: kruger fc.
N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13.
N Engl J Med. 2024.
PMID: 37962077
Clinical Trial.
Item in Clipboard
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group.
Feagan BG, et al.
N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
N Engl J Med. 2016.
PMID: 27959607
Free article.
Clinical Trial.
Item in Clipboard
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators.
Sandborn WJ, et al.
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93.e2. doi: 10.1016/j.cgh.2014.01.029. Epub 2014 Jan 27.
Clin Gastroenterol Hepatol. 2014.
PMID: 24480677
Clinical Trial.
Item in Clipboard
Cite
Cite